Information Center
Xinkanghe Biological XKH002 Clinical Trial Application (IND) Approved in China
Release time:
2023-06-13 09:53
Beijing, China, Suzhou, Jiangsu,On June 12, 2023, XinKangHe Bio, an innovative drug development company, announced that its independently developed innovative drug B7S1 blocking antibody XKH002 for the treatment of tumors has received clinical trial application (IND) approval from China's NMPA..As a "first-in-class" B7S1 blocking antibody, XKH002 has great development potential, especially for patients who do not respond to PD-1/PD-L1 antibody drug treatment, are insensitive to it, or have developed resistance.This yearIn February, XKH002's IND in the United States was approved by the FDA, and after this IND approval in China,XinKangHe will rapidly advance the clinical development of this product.
About XKH002
XKH002 is a recombinant humanized IgG4 monoclonal antibody that blocks B7S1, independently developed by XinKangHe Bio. XKH002 can specifically bind to B7S1 and effectively block the inhibitory effect of B7S1 on T cell proliferation and immune response. XKH002 helps restore and enhance the body's anti-tumor immune response and has broad-spectrum anti-cancer potential.
About XinKangHe Bio
XinKangHe Bio was established in2015, founded bythe internationally renowned immunologist Academician Dong Chen. The company is based on cutting-edge international immunology research, focusing on the development of macromolecular drugs in the fields of autoimmune diseases and immuno-oncology, committed to creating innovative drugs originating from China,targeting the global market, with independent intellectual property rights, to provide patients with globally innovative or best-in-class treatment options. The company adheres to the"Innovation, Precision, Quality, Focus" research and development philosophy, combining solid basic science with translational medicine, possessing multiple globally independent intellectual property innovative pipeline products and new indications entering clinical stages. XinKangHe will continue to delve into areas of unmet clinical needs in inflammation/autimmune diseases and tumor immunotherapy, and looks forward to deep cooperation with innovative pharmaceutical companies at home and abroad.
xkh002, immunity, drug, innovation, b7s1, clinical
Related News
Beijing Address: A203, Zhongguancun Biomedical Park, No.5, Development Road, Haidian District, Beijing
Zhejiang Address: Floor 8, Building 7, Dongsheng Huigu, 1299 Kehai Avenue, Keqiao District, Shaoxing City, Zhejiang Province
Contact Phone:010-82176552
E-mail:hr@kanovabiopharma.com